BRIEF-Antisense Therapeutics Says Anp To Apply For Dual Listing On Frankfurt Stock Exchange
- ByReuters-
Nov 9 (Reuters) - Antisense Therapeutics Ltd ANP.AX :* ANP TO APPLY FOR DUAL LISTING ON FRANKFURT STOCK EXCHANGE
Symbol | Exchange | Currency |
|---|
Nov 9 (Reuters) - Antisense Therapeutics Ltd ANP.AX :* ANP TO APPLY FOR DUAL LISTING ON FRANKFURT STOCK EXCHANGE
Oct 26 (Reuters) - Antisense Therapeutics Ltd ANP.AX :* US FDA OFFICE OF ORPHAN PRODUCTS DEVELOPMENT GRANTED ORPHAN DRUG DESIGNATION TO ATL1102
Sept 30 (Reuters) - Antisense Therapeutics Ltd ANP.AX :* US FDA GRANTS RARE PEDIATRIC DISEASE DESIGNATION TO ATL1102 FOR TREATMENT OF DMD* POTENTIALLY ELIGIBLE FOR RARE...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Sell | Sell | Buy | Strong Buy |
| Technical Indicators | Buy | Strong Sell | Strong Sell | Strong Buy | Strong Buy |
| Summary | Neutral | Strong Sell | Strong Sell | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 17.63 | 17.95 | 17.52 | -0.06 | -0.34% | 1.28M | Sydney | |||
| 126.81 | 127.69 | 126.20 | +0.17 | +0.13% | 862.55K | Sydney | |||
| 6.58 | 6.80 | 6.45 | -0.340 | -4.91% | 3.55M | Sydney | |||
| 5.53 | 5.61 | 5.52 | 0.00 | 0.00% | 4.67M | Sydney | |||
| 31.97 | 32.10 | 31.45 | +0.47 | +1.49% | 469.07K | Sydney | |||
| 0.04 | 0.00 | 0.00 | -0.003 | -6.98% | 10.00K | Sydney | |||
| 14.72 | 15.18 | 14.64 | -0.19 | -1.27% | 1.02M | Sydney | |||
| 0.105 | 0.00 | 0.00 | 0.000 | 0.00% | 194.54K | Sydney | |||
| 0.835 | 0.00 | 0.00 | +0.010 | +1.21% | 2.88M | Sydney | |||
| 4.42 | 4.45 | 4.38 | -0.02 | -0.45% | 880.75K | Sydney | |||
| 33.56 | 34.43 | 33.56 | -1.06 | -3.06% | 666.17K | Sydney | |||
| 5.70 | 5.79 | 5.67 | -0.020 | -0.35% | 1.70M | Sydney | |||
| 40.71 | 40.89 | 39.89 | +1.46 | +3.72% | 1.46M | Sydney | |||
| 0.22 | 0.00 | 0.00 | +0.010 | +4.76% | 3.59M | Sydney | |||
| 83.81 | 84.05 | 82.63 | +1.64 | +2.00% | 388.19K | Sydney |
Antisense Therapeutics Limited is an Australia-based biotechnology company. The Company is engaged in developing and commercializing antisense pharmaceuticals for unmet markets in rare diseases. The Company's product candidate, ATL1103, is an antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood. ATL1103 is in clinical development for acromegaly. The Company's product candidate, ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. The Company completed a Phase IIa efficacy and safety trial of ATL1102 in multiple sclerosis (MS) patients. The Company is engaged in clinical development of ATL1102 in patients with Duchenne Muscular Dystrophy (DMD). The Company is conducting a Phase II clinical trial of ATL1102 in DMD patients.